Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Justin Gainor, MD; Julia Rotow, MD; and Urs Weber, MD; discuss targeted therapies and immunotherapy to treat advanced non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the role of key actionable biomarkers and current molecular testing strategies in advanced NSCLC
• Evaluate recent clinical trial data on approved and emerging targeted therapies and immunotherapies for advanced NSCLC
• Apply molecular profiling results and clinical characteristics to develop individualized treatment plans for patients with advanced NSCLC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from BioNTech; Iovance Biotherapeutics, Inc.; Lilly; Nuvation Bio; Revolution Medicines, Inc.; and Rigel Pharmaceuticals.

Faculty:

Justin Gainor, MD

Associate Professor of Medicine, Harvard Medical School
Program Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Massachusetts General Hospital
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Fee for Service Recipient: AI Proteins, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Ellipses Pharma, Genentech/Roche, Jazz Pharmaceuticals, Johnson & Johnson, Marina Oncology (Curie), Merck, Novartis, Nuvalent, Pfizer, Revolution Medicine, Rigel, Sanofi, Summit, Tempus; Grant/Research Funding: Moderna, Novartis; Ownership Interests: Dyne Therapeutics (spouse), Ironwood Pharmaceuticals (spouse), Alkeus Pharmaceuticals (spouse)

Julia Rotow, MD

Assistant Professor
Harvard Medical School
Clinical Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, Amgen, AstraZeneca, BioAtla, BlossomHill, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, G1 Therapeutics, Genentech, Gilead, Guardant Health, Jazz Pharmaceuticals, Johnson & Johnson, Merus, Novocure, Nuvalent, Nuvation Bio, Pfizer, Regeneron, Sanofi-Genzyme, Summit Therapeutics, Takeda; Grant/Research Funding: AbbVie, Altor Bioscience, AstraZeneca, Bicycle Therapeutics, BioAtla, Black Diamond, BlossomHill, Blueprint Medicines, Bristol Myers Squibb, Duality, Enliven Therapeutics, EpimAb, ImmunityBio, Loxo Oncology, ORIC Pharmaceuticals, RedCloud Bio, Summit, Synthekine, Regeneron

Urs Weber, MD

Assistant Professor, Thoracic Oncology
Division of Medical Oncology
University of Colorado Anschutz Medical Campus
Aurora, CO

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Janssen Biotech

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including the latest data for ALK- and KRAS G12C-targeting therapies, go to https://www.gotoper.com/courses/tumor-board-optimizing-nsclc-careleveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology-1fgr.

Release Date

July 16, 2026

Expiration Date

July 16, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.